Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2006-08-29
2006-08-29
Schwadron, Ronald B. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S806000, C530S826000, C530S329000, C530S300000, C530S350000, C530S403000, C424S189100, C424S228100, C424S185100, C424S186100, C424S192100, C424S193100, C424S196110, C424S197110, C424S201100, C424S204100, C424S238100, C514S002600, C514S012200
Reexamination Certificate
active
07098303
ABSTRACT:
Immunogenic polypeptides comprising hepatitis C virus (HCV) immunogens are described. The HCV immunogen comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-P he-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8). The immunogenic polypeptide can be coupled to a bacterial toxoid, such as a diphtheria toxoid.
REFERENCES:
patent: 4341761 (1982-07-01), Ganfield et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427783 (1984-01-01), Newman et al.
patent: 4444887 (1984-04-01), Hoffmann
patent: 4466917 (1984-08-01), Nussenzweig et al.
patent: 4472500 (1984-09-01), Milstein et al.
patent: 4491632 (1985-01-01), Wands et al.
patent: 4493890 (1985-01-01), Morris
patent: 4517304 (1985-05-01), Stott et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5308750 (1994-05-01), Melita et al.
patent: 5574132 (1996-11-01), Lacroix
patent: 5728520 (1998-03-01), Weiner et al.
patent: 5747239 (1998-05-01), Wang et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5766845 (1998-06-01), Weiner et al.
patent: 5942234 (1999-08-01), Ralston et al.
patent: 6146633 (2000-11-01), Stevens
patent: 0 116 201 (1984-08-01), None
patent: 0 120 551 (1984-10-01), None
patent: 0 164 556 (1985-12-01), None
patent: 0 259 149 (1988-03-01), None
patent: 0 360 088 (1990-03-01), None
patent: 0 388 232 (1990-09-01), None
patent: 0 468 527 (1992-01-01), None
patent: 0 725 824 (1996-08-01), None
patent: 0 759 937 (1997-03-01), None
patent: WO 89/04669 (1989-06-01), None
patent: 9011089 (1990-10-01), None
patent: WO 90/14436 (1990-11-01), None
patent: WO 90/14837 (1990-12-01), None
patent: WO 92/08734 (1992-05-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 93/04205 (1993-04-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 93/16126 (1993-08-01), None
patent: WO 93/18054 (1993-09-01), None
Weiner et al., PNAS, 89: 3468-3472, 1992.
Choo et al., PNAS USA, 91: 1294-1298, 1994.
Seauer, Gen. Eng. News, 14: 10 and 21, 1994.
Berzofsky et al., “Chapter 8”, from “Fundamentals of Immunology. Second Ed.” Ed. W. E. Paul, Raven Press, 1989, pp. 176, 177, 201, 202.
Taniguchi et al., Virol., 195: 297-301, 1993.
Barrett, J.T.,Basic immunology and its medical application, Second Edition, 1980, 14-17.
Botarelli, P. et al., “T-Lymphocyte Response to Hepatitis C Virus in Different Clinical Courses of Infection”,Gastroenterology, 1993,104, 580-587.
Brennan, M. et al., “The foliclle cells are a major site of vitellogenin inDrosophila melanogaster”,Dev. Biol., 1982, 89, 225-236.
Broach, R., “Construction of High Copy Yeast Vectors Using 2-μm Circle Sequences,”Meth. Enz., 1983, 101, 307-325.
Cha et al., “At least five related, but distinct, hepatitis C viral genotypes exist,”Proc. Natl. Acad. Sci USA, 1992, 89, 7144-7148.
Chakrabarti et al., “Vaccinia Virus Expression Vector: Coexpression of β-Galactosidase Provides Visual Screening of Recombinant Virus Plaques,”Mol. Cell Biol., 1985, 5(12), 3403-3409.
Chan et al., “Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants,”J. Gen. Virol., 1992, 73, 1131-1141.
Choo, Q.L. et al., “Genetic organization and diversity of the hepatitis C virus”,Proc. Natl. Acad. Sci. USA, 1991, 88, 2451-2455.
Choo, Q.L. et al., “Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis”,Br. Med. Bull., 1990, 46(2); 423-441.
Choo, Q.L. et al., “Hepatitis C virus is a distant relative of the flaviviruses and pestiviruses”, inProceedings of the International Meeting on Non-A, Non-B Hepatitis, Shikata, T. et al. (eds.), Tokyo, Japan, Amsterdam: Elsevier, 1991, 47-52.
Choo, Q.L. et al., “Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome”,Science, 1989, 244, 359-362.
Choo, Q.L. et al., “Identification of the major, parenteral non-A, non-B hepatitis agent (hepatitis C virus) using a recombinant cDNA approach”,Seminars in Liver Disease, 1992 12(3), 279-288.
Cofin et al. (eds.),RNA Tumor Viruses, 2nd Edition, Cold Spring Harbor Laboratory, New York, 1985, vol. 2, 17-73.
Cuypers, H.T. et al., “Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus”,J. Clin. Microbiol., 1992, 30(12), 3220-3224.
Cuypers, H.T.M. et al., “Analysis of genomic variability of hepatitis-C virus”,J. Hepatology, 1991,13(Suppl. 4), S15-S19.
DeBoer et al., “The tac promotor: a functional hybrid derived from the trp and lac promoters,”Proc. Natl. Acad. Sci. USA, 1983, 80(1), 21-25.
Erickson, A.L. et al., “Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C”,J. Immunol., 1993, 151(8), 4189-4199.
Fausto-Sterling, A. et al., “Analysis of a newly-isolated temperature-sensitive maternal-effect mutation ofDrosophila melanogaster”, J. Exper. Zoo., 1976, 200, 199-209.
Fiers et al., “Complete nucleotide sequence of SV40 DNA,”Nature, 1978, 273, 113-120.
Goeddel et al., “Synthesis of human fibroblast interferon byE. coli,” Nucl. Acids Res., 1980, 8(18), 4057-4075.
Guntaka R.V. et al., “Effect of 5-Methyllcytidine on virus production in avian sarcoma virus-infected chicken embryo cells”,Virology, 1979, 29(2), 475-482.
Guntaka, R.V. et al., “Effect of dibutyrlcyclic AMP on intracellular levels of avian sarcoma virus specific RNA”,Nature, 1978, 274, 274-276.
Hess et al., “Cooperation of glycolytic enzymes,”J. Adv. Enzyme Reg., 1968, 7, 149-167.
Hitzeman et al., “Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique,”J. Biol. Chem.,, 1980, 255(24), 12073-12080.
Holland et al., “The primary structures of two yeast enolase genes,”J. Biol. Chem., 1981, 256(3), 1385-1395.
Holland et al., “Isolation and identification of yeast messenger ribonucleic acids coding for enolase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate kinase,”Biochem., 1978 17(23), 4900-4907.
Houghton, M. et al., “The hepatitis C virus: Genetic organization, persistence, and vaccine strategies,” inViral Hepatitis and Liver Disease, Nishioka, K. et al. (eds.), Springer-Verlag, Tokyo, 1994, 33-37.
Houghton, M. et al., “Hepatitis C virus: Structure, protein products and processing of the polyprotein precursor”,Curr. Stud. Hematol. Blood Transfus.(Switzerlaned), 1994, 61, 1-11.
Houghton, M. et al., “Hepatitis delta (δ) virus (HDV): Its relationship with introns and plant viroid-like agents and the mapping of immunogenic epitopes within viral polypeptides”,J. Med. Virol., 1987, 21(4) 37A, Abstract 106.
Houghton et al., “Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease,”Hepatology, 1991, 14(2), 381-388.
Jansen et al, “Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity,”Immun. Rev., 1982, 62, 185-216.
Jones et al., “The use of maleimidocaproyloxysuccinimide to prepare malarial peptide carrier immunogens,”J. Immunol. Methods, 1989, 123, 211-216.
Kato et al., “Distribution of plural HCV types in Japan,”Biochem. Biophys. Res. Commun., 1991, 181(1), 279-285.
Kubo, Y. et al. “A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan”,Nucl. Acids Res., 1989, 17(24), 10367-10372.
Lee et al., “A method for preparing β-hCG cooh peptide-carrier conjugat
Houghton Michael
Weiner Amy J.
Harbin Alisa A.
Moran Michael J.
Novartis Vaccines and Diagnostics Inc.
Robins Roberta L.
Schwadron Ronald B.
LandOfFree
Conserved motif of hepatitis C virus E2/NS1 region does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conserved motif of hepatitis C virus E2/NS1 region, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conserved motif of hepatitis C virus E2/NS1 region will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3619756